Long-Term Progression-Free Survival Benefit with Ciltacabtagene Autoleucel in Standard-Risk relapsed/refractory Multiple Myeloma

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Luciano J. Costa, Albert Oriol, Dominik Dytfeld, Salomon Manier, Peter Michael Voorhees, Yi Lin, Myo Htut, Wilfried W. H. Roeloffzen, Phoebe Joy Ho, Urvi A. Shah, Man Zhao, Quanlin Li
+18 more Ágnes Balogh, Katherine Li, Ana Slaughter, Nina Benachour, Carolina Lonardi, Arnab Ghosh, Huabin Sun, Nikoletta K. Lendvai, Tamar Lengil, Nitin Patel, Mythili Koneru, Erika Florendo, Octavio Costa Filho, Vrinda Mahajan, Paula Rodríguez‐Otero, Christopher Sun Strouse, A. Keith Stewart, Surbhi Sidana
DOI: 10.1016/j.jtct.2025.12.208
Cited by: 0

Fields of Study & Subjects

Multiple Myeloma Research and Treatments CAR-T cell therapy research Multiple Sclerosis Research Studies

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S152–S152
Publication date
1 February 2026
Language
EN